PL1622639T3 - Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu - Google Patents

Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu

Info

Publication number
PL1622639T3
PL1622639T3 PL04730516T PL04730516T PL1622639T3 PL 1622639 T3 PL1622639 T3 PL 1622639T3 PL 04730516 T PL04730516 T PL 04730516T PL 04730516 T PL04730516 T PL 04730516T PL 1622639 T3 PL1622639 T3 PL 1622639T3
Authority
PL
Poland
Prior art keywords
plasminogen
intravenous injection
treating cerebral
cerebral stroke
neurotoxic
Prior art date
Application number
PL04730516T
Other languages
English (en)
Polish (pl)
Inventor
Mariola Söhngen
Wolfgang Söhngen
Wolf-Dieter Schleuning
Robert Medcalf
Original Assignee
Lundbeck H As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/004729 external-priority patent/WO2004096267A1/de
Application filed by Lundbeck H As filed Critical Lundbeck H As
Publication of PL1622639T3 publication Critical patent/PL1622639T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL04730516T 2003-05-02 2004-04-30 Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu PL1622639T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EPPCT/EP2003/004608 2003-05-02
PCT/EP2003/004729 WO2004096267A1 (de) 2003-05-02 2003-05-06 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
PCT/EP2004/004626 WO2004096268A2 (de) 2003-05-02 2004-04-30 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall
EP04730516A EP1622639B1 (de) 2003-05-02 2004-04-30 Intravenöse injektion nicht-neurotoxischer plasminogen-aktivatoren zur behandlung von schlaganfall

Publications (1)

Publication Number Publication Date
PL1622639T3 true PL1622639T3 (pl) 2013-06-28

Family

ID=35610451

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04730516T PL1622639T3 (pl) 2003-05-02 2004-04-30 Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu

Country Status (10)

Country Link
EP (1) EP1622639B1 (https=)
JP (1) JP2006525270A (https=)
KR (1) KR101212631B1 (https=)
BR (1) BRPI0409865A (https=)
CA (1) CA2524573A1 (https=)
HR (1) HRP20050903B1 (https=)
NO (1) NO337485B1 (https=)
NZ (1) NZ543367A (https=)
PL (1) PL1622639T3 (https=)
WO (1) WO2004096268A2 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US7759506B2 (en) 2002-02-25 2010-07-20 Diffusion Pharmaceuticals Llc Bipolar trans carotenoid salts and their uses
DE10342518A1 (de) * 2003-09-12 2005-05-12 Paion Gmbh Plasminogen-Aktivatoren mit verringerter Lysin-Bindungskapazität
EP2540696B1 (en) 2005-02-24 2020-01-01 Diffusion Pharmaceuticals LLC Trans carotenoids, formulation and uses
EP1897554A1 (en) * 2006-08-25 2008-03-12 PAION Deutschland GmbH Method for the manufacture of a medicament for treating hemorrhagic stroke
WO2008022801A1 (en) * 2006-08-25 2008-02-28 Paion Deutschland Gmbh Method for the manufacture of a medicament for treating hemorrhagic stroke
CN101687757A (zh) 2007-04-13 2010-03-31 扩散药品有限公司 双极性反式类胡萝卜素作为预治疗及其在周围血管疾病的治疗中的应用
PT2440230T (pt) 2009-06-10 2021-02-03 Nono Inc Regimes de tratamento para tratamento de doenças neurológicas
EP2445339B1 (en) * 2009-06-22 2019-08-07 Diffusion Pharmaceuticals LLC Diffusion enhancing compound and its use with a thrombolytic
US8652476B2 (en) 2009-07-27 2014-02-18 Niigata University Pharmaceutical composition for treating ischemic events
JP5823671B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 免疫製剤を含む脳梗塞治療用医薬品組成物
JP5823672B2 (ja) * 2009-07-27 2015-11-25 国立大学法人 新潟大学 受容体シグナル伝達阻害剤を含む脳梗塞治療用医薬品組成物
AU2011262361A1 (en) 2010-06-02 2013-01-10 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
EP2723363B1 (en) * 2011-06-24 2018-08-29 NoNO Inc. Combination therapy for ischemia
US9241970B2 (en) 2011-12-13 2016-01-26 Nono Inc. Therapy for subarachnoid hemorrhage and ischemia
CA3018550A1 (en) 2016-03-24 2017-09-28 Diffusion Pharmaceuticals Llc Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
US10617756B2 (en) 2017-01-05 2020-04-14 Shimojani, LLC Drug regimen for treatment of cerebral ischemia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE69054B1 (en) * 1988-07-20 1996-08-07 Schering Ag Vampire bat salivary plasminogen activators
NL8902454A (nl) * 1989-10-03 1991-05-01 Stichting Centraal Lab Mutanten van de humane plasminogeen activator inhibitor 1 (pai-1), hun bereiding en toepassing, en recombinante polynucleotiden die voor deze mutanten coderende genetische informatie omvatten.
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Also Published As

Publication number Publication date
WO2004096268A3 (de) 2005-04-21
HRP20050903A2 (en) 2006-08-31
NZ543367A (en) 2010-06-25
BRPI0409865A (pt) 2006-05-16
HRP20050903B1 (hr) 2013-11-22
CA2524573A1 (en) 2004-11-11
NO20055692D0 (no) 2005-12-01
EP1622639A2 (de) 2006-02-08
WO2004096268A2 (de) 2004-11-11
KR101212631B1 (ko) 2012-12-14
NO20055692L (no) 2006-01-30
KR20060020616A (ko) 2006-03-06
NO337485B1 (no) 2016-04-25
JP2006525270A (ja) 2006-11-09
EP1622639B1 (de) 2013-01-16

Similar Documents

Publication Publication Date Title
PL1622639T3 (pl) Dożylne wstrzyknięcie nieneurotoksycznych aktywatorów plazminogenu do leczenia udaru mózgu
EG24106A (en) Machine for injecting liquids
IL173439A0 (en) [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
EP1859914A4 (en) METHOD FOR ADJUSTING THE CASTING CONDITIONS AND METHOD FOR CONTROLLING AN INJECTION MOLDING MACHINE
PL372211A1 (en) Thiazolyl urea compounds for the treatment of cancer
IL174951A0 (en) Method for the production of amino crotonyl compounds
IL183973A0 (en) Spm 927 for add -on therapy of schizophrenia
AU2003295537A8 (en) Methods of treating cerebral ischemia
EP1626692A4 (en) COMPOUNDS FOR TREATING FLAVIVIRUS INFECTIONS
IL175014A0 (en) Method of administering therapeutic injections
HUP0402165A3 (en) Non-neurotoxic plasminogen activating factors for treating stroke
ZA200703704B (en) Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
SI1697383T1 (sl) Postopek za čiščenje takrolimusa
AU2003213596A8 (en) Intraspinal continuous infusion of midazolam hydrochloride for the treatment of pain
HRP20030677A2 (en) Methods of administering epothilone analogs for the treatment of cancer
AU2003296705A1 (en) Method for controlling the production of injection molded parts
ZA200603153B (en) Pyridine compounds as inhibitors of dipetidyl peptidase IV
IL173953A0 (en) Plasminogen activators
IL156566A0 (en) Urokinase plasminogen activator derived octapeptide in the treatment of multiple sclerosis
TW569918U (en) Auxiliary jig for forming mold of needle injecting type label piece
GB2401573B (en) Needle assembly for gas-assisted injection moulding
PL1670841T3 (pl) Sposób wytwarzania mieszanin polioli
SG103892A1 (en) Method of making fibrinogen particles suited for intravenous injections
TW549219U (en) Support sliding seat for fully injecting seat of injecting forming machine
SI1519726T1 (sl) Heteroarenski karboksamidi za uporabo kot ligandi dopamina D3 za zdravljenje bolezni CŽS